FLT3 and acute myeloid leukemia: In our study, quizartinib monotreatment exhibited limited efficacy both in resistant FLT3-ITD AML cells carrying the F691L mutation and in FLT3-ITD+ AML patient samples, particularly in older individuals with high allelic ratios, unlike its significant effectiveness in FLT3-ITD AML cell lines.